Companion Animal Osteoarthritis Market (2025 - 2033)

Companion Animal Osteoarthritis Market Summary

The global companion animal osteoarthritis market size was estimated at USD 2.29 billion in 2024 and is projected to reach USD 13.27 billion by 2033, growing at a CAGR of 23.5% from 2025 to 2033. Key factors expected to drive the market include the rising prevalence of osteoarthritis, increasing R&D initiative, emerging novel treatments, increasing awareness campaigns, and advancing diagnostic techniques increasing adoption of osteoarthritis (OA) treatment.

The rising prevalence of osteoarthritis (OA) in companion animals-particularly dogs, cats, and horses-is significantly driving the global companion animal osteoarthritis market. In canines alone, estimates suggest that approximately 20% of dogs over one year of age show clinical signs of OA, and this prevalence can escalate to as high as 80% in older dogs, according to both clinical observations and radiographic studies. Similar trends are observed in felines, where OA is often underdiagnosed but increasingly recognized in aging cat populations, with some studies indicating radiographic signs in up to 90% of cats over 12 years old. Equine OA also remains a leading cause of reduced performance and early retirement, especially in sport and racehorses.

Several factors are contributing to this increase in OA prevalence, including extended pet lifespans due to advances in nutrition and veterinary care, rising rates of obesity (a major OA risk factor), and improved awareness and diagnostic capabilities among veterinarians and pet owners. These trends are expanding the demand for early diagnosis, chronic disease management, and pain relief solutions.

This growing burden has catalyzed significant investment and innovation in OA therapeutics, including the development of novel biologics, regenerative therapies (e.g., stem cells and PRP), monoclonal antibodies (such as Zoetis’ Librela and Solensia), and other multimodal pain management approaches. Pharmaceutical and biotech companies are actively developing long-acting, targeted therapies that offer better compliance and improved quality of life for pets, particularly as pet owners increasingly seek premium and preventative care. In parallel, the surge in veterinary visits and emphasis on mobility monitoring and wellness programs is reinforcing a robust market for diagnostics, supplements, joint-support diets, and rehabilitation services.

Altogether, these epidemiological and behavioral factors are not only expanding the companion animal OA patient pool but are also transforming the disease into a cornerstone segment of the global animal health industry-creating long-term growth opportunities across therapeutics, diagnostics, and supportive care solutions.

Despite strong market performance and widespread adoption of OA-targeting monoclonal antibodies like Librela, the recent public controversy-including calls for outright bans and new data suggesting a nine‑fold increase in musculoskeletal adverse events-poses a reputational and regulatory challenge. Heightened scrutiny from regulators like the FDA and EMA may result in tougher post‑market surveillance, label revisions, or prescribing restrictions. In the short term, veterinarians and pet owners might pivot toward more conservative options, such as established NSAIDs or supplements, potentially slowing growth in the biologics segment. However, transparent safety studies, improved pharmacovigilance, and clear risk-benefit guidelines could restore confidence and ultimately solidify the position of mAb therapies as a premium OA treatment-assuming manufacturers respond proactively

Common Trigger Factors for Osteoarthritis

Canine -

Feline -

Equine -

Market Concentration & Characteristics

This industry continues to show targeted innovation, particularly in pain management and chronic disease treatment in companion animals. Rather than broad-spectrum developments, companies focus on novel, specialized modalities for conditions like osteoarthritis. For instance, in July 2025, Exubrion Therapeutics launched a groundbreaking radioisotope injection (tin-117m) for canine osteoarthritis, which offers targeted anti-inflammatory effects by selectively disabling overactive macrophages within joints-delivering sustained pain relief with a single intra-articular injection. This approach exemplifies a shift toward minimally invasive, long-acting solutions beyond conventional NSAIDs or monoclonal antibodies.

The market is witnessing moderate Merger & Acquisition (M&A) activity, driven by leading players and the rise of specialist companies dedicated to innovative pain and joint care solutions. These specialized firms actively develop and launch targeted therapies while pursuing strategic acquisitions to expand capabilities. For instance, in March 2023, VetStem, Inc. acquired three new GMP manufacturing and R&D facilities in the San Diego Biopharma corridor to support its accelerating growth in regenerative therapies for osteoarthritis.

Regulations have a significant and growing impact on the companion animal osteoarthritis market, especially with the rise of advanced therapies like monoclonal antibodies. Recent concerns surrounding products such as Librela (Beransa in Australia) have triggered heightened regulatory scrutiny, with increased reports of adverse events prompting public backlash and calls for bans. Agencies like the US FDA and Australia’s APVMA are responding with intensified pharmacovigilance and risk assessments, potentially leading to updated usage guidelines, warning labels, or prescribing limitations. These regulatory responses aim to ensure safety while maintaining access to innovative therapies, creating a more cautious and compliance-heavy landscape for manufacturers and veterinarians alike.

The CA OA market is led by major players such as Zoetis, Boehringer Ingelheim, Dechra Pharmaceuticals plc, and Merck & Co. Inc. However, the use of alternative therapies is rising rapidly, particularly regional and non-pharmaceutical options, due to factors like cost sensitivity and growing owner preference for natural solutions. For instance, products incorporating cannabidiol (CBD) are gaining traction as substitutes or complements to conventional OA treatments. Fusion CBD Products, for example, recently launched a new line of CBD-based pet formulations aimed at addressing chronic pain and mobility issues, reflecting the growing interest in plant-based and wellness-focused alternatives in the CA OA space.

The market is benefiting from notable regional expansion, as companies look to broaden their geographic reach through strategic deals. A compelling example comes from the Indian market: in July 2025, Fredun Pharmaceuticals formally entered the pet‑care sector by acquiring a controlling stake in One Pet Stop-a fast-growing, tech‑enabled mobile grooming and pet health services provider with over 4,000 loyal customers in urban centers such as Mumbai’s MMRDA region. This acquisition allows Fredun to pair its manufacturing and distribution strengths with on‑the‑ground service delivery, helping introduce novel osteoarthritis treatments and supportive-care products directly to pet owners across India.

Product Insights

The biologics segment-comprising monoclonal antibodies (mAbs), stem cells, and platelet-rich plasma (PRP)-is dominating the market with a share of 53.9% in 2024 and is expected to grow at the fastest rate over the forecast period due to its superior efficacy, longer duration of action, and minimal side effects compared to traditional NSAIDs. Monoclonal anitbodies (mAbs) like Zoetis’ Librela (for dogs) and Solensia (for cats) have seen exponential uptake since their launches, and are expanding into multiple markets including the U.S., EU, and Asia-Pacific.

These therapies offer monthly, targeted pain relief with high owner compliance. At the same time, regenerative treatments like stem cell therapy and PRP are gaining traction in both veterinary clinics and equine sports medicine due to their ability to modulate inflammation and support joint repair. Stem cell use is particularly growing in dogs and horses with chronic OA, while PRP is now being explored more routinely for feline patients as well. The premium pricing, expanding clinical evidence, and rising owner willingness to invest in advanced, long-lasting care solutions are collectively fueling the biologics segment's growth trajectory.

Animal Insights

The canine segment is dominating the companion animal osteoarthritis market with a share of around 47% in 2024 and is projected to grow at the fastest rate over the forecast period due to the high prevalence of osteoarthritis in dogs, increasing pet ownership, and growing awareness among owners about pain management options. Dogs are more frequently diagnosed with OA compared to other species, with up to 20-40% affected by clinical signs, especially in older or larger breeds.

A major growth catalyst was the U.S. FDA approval and commercial launch of Zoetis’ Librela in May 2023, which brought targeted monoclonal antibody therapy for canine OA pain to one of the largest pet markets globally. This has significantly increased market penetration and set a new standard for chronic pain treatment in dogs. Additionally, the rising trend of pet humanization, premium spending on dog healthcare, and expanded veterinary diagnostics and mobility monitoring are further accelerating growth in this segment.

Route of Administration Insights

The injectables segment-including intra-articular, intramuscular, and subcutaneous formulations-is dominating the companion animal osteoarthritis market in 2024 and is expected to grow at fastest rate of 26.05% over the forecast period due to their superior efficacy and targeted delivery. Injectables provide rapid onset of action and longer-lasting relief compared to oral or topical treatments, which often require daily administration and have variable absorption. Intra-articular injections, such as stem cell therapies and monoclonal antibodies such as Librela, directly target affected joints, improving outcomes and reducing systemic side effects.

Additionally, the convenience of less frequent dosing improves owner compliance and pet comfort. Advances in injectable biologics and regenerative therapies have expanded treatment options, driving adoption among veterinarians. This has shifted preference away from traditional oral NSAIDs and topical products, positioning injectables as the preferred choice for long-term management of osteoarthritis in companion animals.

End Use Insights

The veterinary hospitals/clinics segment dominates the companion animal osteoarthritis market in 2024 due to their role as primary points of diagnosis, treatment, and ongoing management of OA in pets. These facilities offer advanced diagnostic tools, access to novel and specialized therapies like monoclonal antibodies and regenerative treatments, and professional expertise required for administering injectables and complex care. Increased pet owner visits, rising awareness of OA, and growing demand for premium veterinary services drive higher treatment uptake in clinics. Furthermore, veterinary hospitals provide personalized care and follow-up, fostering greater treatment adherence and reinforcing their market dominance.

The e-commerce segment is expected to grow at the fastest growth rate over the forecast period in the companion animal osteoarthritis market due to the rising demand for convenience, affordability, and direct-to-door delivery of pet medications and supplements. As more pet owners turn to online platforms for recurring OA treatments like joint supplements, prescription refills, and wellness products, digital channels are gaining traction. The growth of online veterinary pharmacies, auto-ship options, and telehealth integrations further supports this trend. Additionally, increasing internet penetration and pet e-commerce platforms offering competitive pricing and educational content are making it easier for owners to manage chronic conditions like osteoarthritis from home.

Regional Insights

North America companion animal osteoarthritis market remains the largest market, driven by high pet ownership, early adoption of novel biologics, and strong veterinary infrastructure. Increased awareness of chronic pain in aging pets and growing demand for premium pet healthcare are also contributing to sustained market expansion.

U.S. Companion Animal Osteoarthritis Market Trends

The U.S. market is witnessing rapid growth following the 2023 FDA approval of Librela, boosting adoption of monoclonal antibodies. Additionally, rising use of digital veterinary platforms and pet insurance coverage is improving access to advanced OA therapies.

Europe Companion Animal Osteoarthritis Market Trends

Europe shows steady growth due to widespread veterinary access, aging pet populations, and supportive regulations for biologic approvals. Preventative care initiatives and mobility monitoring are becoming more common in countries with high veterinary service utilization.

Germany companion animal osteoarthritis market is shaped by strong demand for natural and regenerative therapies, including stem cells and PRP, reflecting a preference for integrative care. Increasing investments in veterinary R&D and domestic biologic manufacturing also support innovation.

Asia Pacific Companion Animal Osteoarthritis Market Trends

Asia Pacific is emerging as a high-growth region fueled by increasing urban pet ownership, expanding middle class, and growing investment in veterinary infrastructure. Awareness campaigns and government support in pet welfare are also accelerating demand.

Companion animal osteoarthritis market in India is rapidly evolving with rising awareness of canine OA and increased spending on pet wellness. Local companies like Fredun Pharmaceuticals are entering the market space through strategic acquisitions, aiming to introduce new treatments regionally.

Latin America Companion Animal Osteoarthritis Market Trends

Latin America’s growth is driven by improving veterinary access and increasing interest in affordable OA management solutions. There's a rising trend of veterinarians adopting injectable therapies over traditional pain relievers in urban areas

Brazil companion animal osteoarthritis market leads the region with a large pet population and growing preference for advanced therapies like Librela and stem cell treatments. Local veterinary networks are expanding services related to chronic pain management and mobility assessment.

Middle East & Africa Companion Animal Osteoarthritis Market Trends

The market here is developing lucratively, supported by rising pet adoption in affluent urban centers and investment in veterinary education. Import of biologics and premium supplements is increasing, though accessibility remains limited in rural regions.

Companion animal osteoarthritis market in South Africa is seeing moderate growth with expanding private veterinary clinics and increased demand for long-acting injectables. Educational outreach on pet mobility and wellness is helping to shift owner preference toward proactive OA management.

Key Companion Animal Osteoarthritis Companies & Market Share Insights

The companion animal osteoarthritis (CA OA) market reflects a dynamic and rapidly evolving ecosystem that is also influencing growth in the pet insurance industry. With targeted innovation in pain management-such as radioisotope injections and monoclonal antibodies-treatment costs are rising, prompting more pet owners to seek insurance coverage to manage chronic conditions affordably. As regulatory scrutiny increases and new therapies enter the market, insurance providers are adapting policies to include advanced treatments like stem cell therapy and CBD-based products. Simultaneously, regional expansion and growing demand for wellness-focused alternatives are broadening the scope of services pet insurers must consider. This evolving landscape is making pet insurance not just a luxury but a necessity for long-term care, especially for aging pets prone to osteoarthritis.

Recent Developments

• In July 2025, Fredun Pharmaceuticals entered India’s pet care market through the acquisition of a majority stake in One Pet Stop, a tech‑based grooming and health‑management service with over 4,000 customers across Mumbai’s urban region. By integrating One Pet Stop’s doorstep services with its Freossi pet healthcare brand and distribution network, Fredun aims to enhance its reach and introduce advanced pet wellness solutions across key Indian cities.

• In March 2025, Vetbiolix, Can‑Fite’s veterinary partner, initiated an advanced clinical trial of their oral A3 adenosine receptor agonist, Piclidenoson, in dogs with osteoarthritis-building on earlier positive efficacy and safety results.

Companion Animal Osteoarthritis Market